[
  {
    "row_id": "ROW_151",
    "regimen": "emerging therapies for lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_151"
  },
  {
    "row_id": "ROW_154",
    "regimen": "DLL3 targeting in lung cancers of neuroendocrine origin",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_154"
  },
  {
    "row_id": "2986eP",
    "regimen": "identifying a population at risk in lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2986eP"
  },
  {
    "row_id": "3172eP",
    "regimen": "predictive value of LIPI score in immunotherapy response",
    "drugs": [],
    "biomarkers": [
      "LIPI"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "3172eP"
  },
  {
    "row_id": "1882P",
    "regimen": "population-level real-world evidence in lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1882P"
  },
  {
    "row_id": "1",
    "regimen": "Combined Blockade of KRAS and PRMT5",
    "drugs": [
      "KRAS",
      "PRMT5"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2248P"
  },
  {
    "row_id": "2",
    "regimen": "First-Line anti-EGFR Therapy",
    "drugs": [
      "anti-EGFR"
    ],
    "biomarkers": [
      "DNA Methylation"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "817P"
  },
  {
    "row_id": "3",
    "regimen": "toripalimab, cetuximab plus FOLFIRI",
    "drugs": [
      "toripalimab",
      "cetuximab",
      "FOLFIRI"
    ],
    "biomarkers": [
      "RAS",
      "BRAF"
    ],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "866eP"
  },
  {
    "row_id": "4",
    "regimen": "HRS-4642 Combined with Gemcitabine and Nab-paclitaxel",
    "drugs": [
      "HRS-4642",
      "Gemcitabine",
      "Nab-paclitaxel"
    ],
    "biomarkers": [
      "KRAS-G12D"
    ],
    "modality": [
      "ADC",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1b/2",
    "trial_id": "2215O"
  },
  {
    "row_id": "5",
    "regimen": "DS-3939 in advanced/metastatic solid tumors",
    "drugs": [
      "DS-3939"
    ],
    "biomarkers": [
      "TA-MUC1"
    ],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "917O"
  },
  {
    "row_id": "6",
    "regimen": "Conversion Therapy With Encorafenib + Cetuximab",
    "drugs": [
      "Encorafenib",
      "Cetuximab"
    ],
    "biomarkers": [
      "BRAF V600E"
    ],
    "modality": [
      "TKI",
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "880eP"
  },
  {
    "row_id": "7",
    "regimen": "Predictive biomarker to anti-EGFR therapy",
    "drugs": [
      "anti-EGFR"
    ],
    "biomarkers": [
      "Lactate dehydrogenase",
      "RAS",
      "BRAF"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "814P"
  },
  {
    "row_id": "8",
    "regimen": "Optimised adaptive strategies with systemic therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_2457"
  },
  {
    "row_id": "9",
    "regimen": "Frontline Anti-VEGF and Anti-EGFR Exposure",
    "drugs": [
      "Trifluridine",
      "Tipiracil",
      "Regorafenib"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "792P"
  },
  {
    "row_id": "10",
    "regimen": "Welcome and introductions",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_2470"
  },
  {
    "row_id": "11",
    "regimen": "systemic mitochondrial alterations in lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "224eP"
  },
  {
    "row_id": "12",
    "regimen": "DNA mutation and methylation evolution in lung adenocarcinoma",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "3042eP"
  },
  {
    "row_id": "13",
    "regimen": "targeted therapy in BRAF-mutant glioblastomas",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "687P"
  },
  {
    "row_id": "14",
    "regimen": "efficacy of second-line BRAF/MEK inhibitors",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "1646P"
  },
  {
    "row_id": "15",
    "regimen": "clinical efficacy of PD-1/CTLA-4 bispecific antibody",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "18P"
  },
  {
    "row_id": "16",
    "regimen": "external validation of Rachel score",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1721P"
  },
  {
    "row_id": "17",
    "regimen": "interlesional heterogeneity of EGFR mutations",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "249eP"
  },
  {
    "row_id": "18",
    "regimen": "real-world treatment patterns in NTRK+ tumors",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "171P"
  },
  {
    "row_id": "19",
    "regimen": "efficacy and safety of anlotinib plus sintilimab",
    "drugs": [
      "Anlotinib",
      "Sintilimab"
    ],
    "biomarkers": [],
    "modality": [
      "TKI",
      "IO"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "2991P"
  },
  {
    "row_id": "2073eP",
    "regimen": "Adherence to Tumor Board Recommendations",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2073eP"
  },
  {
    "row_id": "1927P",
    "regimen": "Tracking Myeloid Cells Variation",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1927P"
  },
  {
    "row_id": "2055eP",
    "regimen": "Occupational Exposure to Carcinogens",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2055eP"
  },
  {
    "row_id": "ROW_655",
    "regimen": "Diagnosis and treatment of G3 lung NET",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_655"
  },
  {
    "row_id": "1897P",
    "regimen": "PD-1/IL-2 Bispecific Antibody",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1897P"
  },
  {
    "row_id": "2978P",
    "regimen": "AI-defined Lung Nodule Malignancy Score",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "2978P"
  },
  {
    "row_id": "ROW_719",
    "regimen": "Lung",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_719"
  },
  {
    "row_id": "ROW_730",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_730"
  },
  {
    "row_id": "ROW_733",
    "regimen": "Q&A & discussion",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_733"
  },
  {
    "row_id": "ROW_734",
    "regimen": "Conclusion remarks",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_734"
  },
  {
    "row_id": "2975P",
    "regimen": "Barriers to lung cancer screening",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2975P"
  },
  {
    "row_id": "1873P",
    "regimen": "Ipilimumab Plus Nivolumab With or Without Chemotherapy",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1873P"
  },
  {
    "row_id": "1925P",
    "regimen": "Single cell RNA-sequencing reveals IGFBP3+ CAFs",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1925P"
  },
  {
    "row_id": "1968P",
    "regimen": "MedSR (Median Short Fragment Ratio)",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1968P"
  },
  {
    "row_id": "ROW_796",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_796"
  },
  {
    "row_id": "1951P",
    "regimen": "Companion diagnostic assay for c-Met protein overexpression",
    "drugs": [
      "telisotuzumab vedotin"
    ],
    "biomarkers": [
      "c-Met"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1951P"
  },
  {
    "row_id": "ROW_803",
    "regimen": "Harnessing the immune system for cancer prevention",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_803"
  },
  {
    "row_id": "2077eP",
    "regimen": "Evaluation of efficacy differences among three treatment modalities",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2077eP"
  },
  {
    "row_id": "2072eP",
    "regimen": "Predicting Brain Metastasis at the Time of Diagnosis",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2072eP"
  },
  {
    "row_id": "ROW_866",
    "regimen": "Relentless research for novel treatment options",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_866"
  },
  {
    "row_id": "1906P",
    "regimen": "first-line immune checkpoint inhibitors",
    "drugs": [
      "immune checkpoint inhibitors"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1906P"
  },
  {
    "row_id": "1900P",
    "regimen": "high-intensity interval training",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1900P"
  },
  {
    "row_id": "2000P",
    "regimen": "selective RET inhibitor",
    "drugs": [
      "selective RET inhibitor"
    ],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2000P"
  },
  {
    "row_id": "2050eP",
    "regimen": "analysis of prognostic factors",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2050eP"
  },
  {
    "row_id": "2069eP",
    "regimen": "molecular targeted agents",
    "drugs": [
      "molecular targeted agents"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2069eP"
  },
  {
    "row_id": "2776P",
    "regimen": "DLL3-targeting antibody therapies",
    "drugs": [
      "DLL3-targeting antibody therapies"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2776P"
  },
  {
    "row_id": "2987O",
    "regimen": "Dabrafenib Plus Trametinib",
    "drugs": [
      "Dabrafenib",
      "Trametinib"
    ],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2987O"
  },
  {
    "row_id": "3194eP",
    "regimen": "short films as tool in lung cancer communication",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "3194eP"
  },
  {
    "row_id": "2070eP",
    "regimen": "Pemetrexed-Based Chemo-Immunotherapy",
    "drugs": [
      "Pemetrexed"
    ],
    "biomarkers": [
      "TTF-1",
      "PD-L1"
    ],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2070eP"
  },
  {
    "row_id": "1913P",
    "regimen": "targeted therapy",
    "drugs": [
      "ctDNA Testing"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1913P"
  },
  {
    "row_id": "1956P",
    "regimen": "osimertinib then chemotherapy",
    "drugs": [
      "osimertinib",
      "chemotherapy"
    ],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [
      "TKI",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "3L",
    "phase": "Not specified",
    "trial_id": "1956P"
  },
  {
    "row_id": "1832P",
    "regimen": "remodel lung adenocarcinoma immune microenvironment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1832P"
  },
  {
    "row_id": "2016P",
    "regimen": "neuropsychological assessment and brain imaging",
    "drugs": [
      "atezolizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2016P"
  },
  {
    "row_id": "3175eP",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ICARUS-LUNG01"
  },
  {
    "row_id": "ROW_1216",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "2065eP",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1980P",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [
      "ALK",
      "TMB"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "ABP"
  },
  {
    "row_id": "1814eP",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1866P",
    "regimen": "camrelizumab plus famitinib",
    "drugs": [
      "camrelizumab",
      "famitinib"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "CAPSTONE"
  },
  {
    "row_id": "2066eP",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1977P",
    "regimen": "not specified",
    "drugs": [
      "SGR-5573"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1898P",
    "regimen": "not specified",
    "drugs": [
      "pembrolizumab"
    ],
    "biomarkers": [
      "PD-1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "2053eP",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [
      "EGFR",
      "ALK"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "WAYFIND-R"
  },
  {
    "row_id": "ROW_1320",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "ROW_1322",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "2009P",
    "regimen": "chemotherapy and tyrosine kinase inhibition",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "ROW_1369",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "3193eP",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1961P",
    "regimen": "osimertinib monotherapy",
    "drugs": [
      "osimertinib"
    ],
    "biomarkers": [
      "TP53"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "2780P",
    "regimen": "not specified",
    "drugs": [
      "BL0020"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "not specified"
  },
  {
    "row_id": "ROW_1421",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1830P",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "1793P",
    "regimen": "not specified",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "not specified"
  },
  {
    "row_id": "2040eP",
    "regimen": "treatment-naive, driver-negative metastatic lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2040eP"
  },
  {
    "row_id": "1805eP",
    "regimen": "microwave ablation versus lobectomy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1805eP"
  },
  {
    "row_id": "1812eP",
    "regimen": "IO treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1812eP"
  },
  {
    "row_id": "2047eP",
    "regimen": "large language models in multidisciplinary planning",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2047eP"
  },
  {
    "row_id": "2049eP",
    "regimen": "osimertinib rechallenge",
    "drugs": [
      "osimertinib"
    ],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2049eP"
  },
  {
    "row_id": "CN158",
    "regimen": "association between genetic risk and lung cancer risk",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "CN158"
  },
  {
    "row_id": "1800P",
    "regimen": "lower CT nodule thresholds in lung cancer screening",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1800P"
  },
  {
    "row_id": "1909P",
    "regimen": "radiological and molecular patterns of metastatic growth",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1909P"
  },
  {
    "row_id": "1892P",
    "regimen": "treatment and prognosis of lung cancer in young patients",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1892P"
  },
  {
    "row_id": "2008P",
    "regimen": "frontline TKIs",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2008P"
  },
  {
    "row_id": "1799P",
    "regimen": "uniportal video-assisted thoracoscopic surgery",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1799P"
  },
  {
    "row_id": "1903P",
    "regimen": "antibiotic exposure before or during immune checkpoint inhibitor therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1903P"
  },
  {
    "row_id": "ROW_1686",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_1686"
  },
  {
    "row_id": "2838P",
    "regimen": "trastuzumab deruxtecan-induced interstitial lung disease",
    "drugs": [
      "trastuzumab deruxtecan"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2838P"
  },
  {
    "row_id": "LBA84",
    "regimen": "GFH375 monotherapy",
    "drugs": [
      "GFH375"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "LBA84"
  },
  {
    "row_id": "2186P",
    "regimen": "pre-treatment inflammation and long-term cancer-related fatigue",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2186P"
  },
  {
    "row_id": "853P",
    "regimen": "anti-EGFR resistance mutations",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "853P"
  },
  {
    "row_id": "2371eP",
    "regimen": "scalable implementation of a thoracic tumor functional unit",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2371eP"
  },
  {
    "row_id": "886eP",
    "regimen": "impact of RAS and BRAF mutations on immunotherapy outcomes",
    "drugs": [],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "886eP"
  },
  {
    "row_id": "ROW_1793",
    "regimen": "optimised adaptive strategies with radiotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_1793"
  },
  {
    "row_id": "928P",
    "regimen": "MET-TKI DO-2",
    "drugs": [
      "DO-2"
    ],
    "biomarkers": [
      "MET"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "928P"
  },
  {
    "row_id": "882eP",
    "regimen": "Intratumoural IVX037",
    "drugs": [
      "IVX037"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "882eP"
  },
  {
    "row_id": "2884P",
    "regimen": "Multimodal Care for Lung Cancer Patients",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2884P"
  },
  {
    "row_id": "995P",
    "regimen": "Effect of High-Fat Meal on DO-2",
    "drugs": [
      "DO-2"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "995P"
  },
  {
    "row_id": "2848P",
    "regimen": "Anticoagulation Strategies in Lung Cancer Patients",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2848P"
  },
  {
    "row_id": "914O",
    "regimen": "HRS-7058 in advanced solid tumors",
    "drugs": [
      "HRS-7058"
    ],
    "biomarkers": [
      "KRAS G12C",
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "914O"
  },
  {
    "row_id": "915O",
    "regimen": "KRAS G12D inhibitor HRS-4642",
    "drugs": [
      "HRS-4642"
    ],
    "biomarkers": [
      "KRAS G12D",
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "915O"
  },
  {
    "row_id": "972P",
    "regimen": "Neladalkib efficacy and safety",
    "drugs": [
      "Neladalkib"
    ],
    "biomarkers": [
      "ALK"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "972P"
  },
  {
    "row_id": "2005",
    "regimen": "Implementing shared decision-making",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2005"
  },
  {
    "row_id": "2006",
    "regimen": "Discussion",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2006"
  },
  {
    "row_id": "2031",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2031"
  },
  {
    "row_id": "1994",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1994"
  },
  {
    "row_id": "2067",
    "regimen": "Defining an unfit population",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2067"
  },
  {
    "row_id": "2106",
    "regimen": "Presentation of case/condition",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2106"
  },
  {
    "row_id": "2959eP",
    "regimen": "EGFR-targeted monoclonal antibodies",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2959eP"
  },
  {
    "row_id": "2961eP",
    "regimen": "Carboplatin dose calculation",
    "drugs": [
      "Carboplatin",
      "carboplatin"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "2961eP"
  },
  {
    "row_id": "1829",
    "regimen": "First-line strategies",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1829"
  },
  {
    "row_id": "1809",
    "regimen": "Patient supportive care",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1809"
  },
  {
    "row_id": "932P",
    "regimen": "amivantamab in subjects with aberrant MET and/or EGFR solid tumors",
    "drugs": [
      "Amivantamab"
    ],
    "biomarkers": [
      "MET",
      "EGFR"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "Baskets of Baskets"
  },
  {
    "row_id": "1016eTiP",
    "regimen": "LY4066434 in KRAS-mutant solid tumors",
    "drugs": [
      "LY4066434"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "Trial in Progress"
  },
  {
    "row_id": "2932eP",
    "regimen": "lung cancer patient navigator for toxicities management",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2880P",
    "regimen": "effect of physical activities in long-term survivors of lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2204eP",
    "regimen": "palliative care management in lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "875eP",
    "regimen": "EGFR-, VEGF-inhibitors or no biologics with first line combination chemotherapy",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "835P",
    "regimen": "encorafenib plus cetuximab in BRAF V600E-mutated colorectal carcinoma",
    "drugs": [
      "Encorafenib",
      "Cetuximab"
    ],
    "biomarkers": [
      "BRAF V600E"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": ""
  },
  {
    "row_id": "1558P",
    "regimen": "REGN7075 in patients receiving bispecific antibody",
    "drugs": [
      "REGN7075"
    ],
    "biomarkers": [],
    "modality": [
      "Bispecific"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": ""
  },
  {
    "row_id": "728MO",
    "regimen": "predictive value of low-frequency resistance mutations in anti-EGFR rechallenge",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2610MO",
    "regimen": "genomic analysis of papillary renal cell carcinoma",
    "drugs": [],
    "biomarkers": [
      "MET"
    ],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "837P",
    "regimen": "impact of TP53 gain of function mutations on clinical outcomes",
    "drugs": [],
    "biomarkers": [
      "TP53"
    ],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2944eP",
    "regimen": "decreased risk of radiation pneumonitis with valsartan",
    "drugs": [
      "Valsartan"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2580eP",
    "regimen": "causal relationships between personality traits and lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2373eP",
    "regimen": "barriers undermining lung cancer screening",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2602",
    "regimen": "geographic variation in somatic genomics of lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2491",
    "regimen": "summary and take-home messages",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2572",
    "regimen": "tackling EGFR treatment resistance",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "20",
    "regimen": "patient-derived organoids response to KRAS inhibition",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "78eP"
  },
  {
    "row_id": "1413P",
    "regimen": "Cisplatin Chemoresistance",
    "drugs": [
      "Cisplatin",
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1413P"
  },
  {
    "row_id": "540P",
    "regimen": "post-trastuzumab deruxtecan treatment",
    "drugs": [
      "trastuzumab deruxtecan"
    ],
    "biomarkers": [
      "HER2"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "540P"
  },
  {
    "row_id": "3022eP",
    "regimen": "Radioresistance promotion",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "3022eP"
  },
  {
    "row_id": "1762eP",
    "regimen": "Non-Invasive Tool for Lung Cancer Detection",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1762eP"
  },
  {
    "row_id": "4086",
    "regimen": "ADC Design and Evaluation",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "4086"
  },
  {
    "row_id": "ROW_4088",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4107",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4132",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1699eP",
    "regimen": "encorafenib plus binimetinib",
    "drugs": [
      "encorafenib",
      "binimetinib"
    ],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "720eP",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4158",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "34eP",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "173TiP",
    "regimen": "Circulating tumour DNA guided Adaptive BRAF and MEK Inhibitor therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 2",
    "trial_id": "DyNAMIc"
  },
  {
    "row_id": "276eP",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4250",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "218eP",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "9P",
    "regimen": "amivantamab",
    "drugs": [
      "amivantamab"
    ],
    "biomarkers": [
      "MET"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "124P",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4302",
    "regimen": "",
    "drugs": [],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "3002P",
    "regimen": "Dabrafenib Plus Trametinib",
    "drugs": [
      "Dabrafenib",
      "Trametinib"
    ],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1654P",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2998P",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4384",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1784eP",
    "regimen": "salivary exosome-based liquid biopsy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1514O",
    "regimen": "TCR-T therapy targeting KRAS G12V",
    "drugs": [],
    "biomarkers": [
      "KRAS G12V",
      "KRAS"
    ],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "926MO",
    "regimen": "MK-1084 Monotherapy",
    "drugs": [
      "MK-1084"
    ],
    "biomarkers": [
      "KRAS G12C",
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "KANDLELIT-001"
  },
  {
    "row_id": "927MO",
    "regimen": "single-agent divarasib",
    "drugs": [
      "divarasib"
    ],
    "biomarkers": [
      "KRAS G12C",
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "927MO"
  },
  {
    "row_id": "ROW_163",
    "regimen": "c-Met protein directed strategies",
    "drugs": [],
    "biomarkers": [
      "c-Met"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_163"
  },
  {
    "row_id": "2022P",
    "regimen": "immunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2022P"
  },
  {
    "row_id": "2650P",
    "regimen": "metastasis-directed therapies",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2650P"
  },
  {
    "row_id": "1918P",
    "regimen": "evaluation of a GPT-based conversational AI tool",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1918P"
  },
  {
    "row_id": "1921P",
    "regimen": "computational modeling for rare mutations",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1921P"
  },
  {
    "row_id": "1798P",
    "regimen": "molecular landscape prediction",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1798P"
  },
  {
    "row_id": "1808eP",
    "regimen": "bronchoalveolar lavage",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1808eP"
  },
  {
    "row_id": "2013P",
    "regimen": "repotrectinib",
    "drugs": [
      "repotrectinib"
    ],
    "biomarkers": [
      "NTRK"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2013P"
  },
  {
    "row_id": "1815eP",
    "regimen": "Aumolertinib",
    "drugs": [
      "Aumolertinib"
    ],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "1815eP"
  },
  {
    "row_id": "LBA33",
    "regimen": "ctDNA-Guided Anti-EGFR Rechallenge",
    "drugs": [
      "Anti-EGFR"
    ],
    "biomarkers": [
      "ctDNA"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "CITRIC"
  },
  {
    "row_id": "1940P",
    "regimen": "Cerebrospinal Fluid cfDNA Analysis",
    "drugs": [],
    "biomarkers": [
      "cfDNA"
    ],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1940P"
  },
  {
    "row_id": "1833P",
    "regimen": "Multi-marker methylation panel (epiLung)",
    "drugs": [],
    "biomarkers": [
      "methylation markers"
    ],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1833P"
  },
  {
    "row_id": "2045eP",
    "regimen": "Perivascular Spaces as Immune Gatekeepers",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2045eP"
  },
  {
    "row_id": "1797P",
    "regimen": "Clinical risk stratification",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1797P"
  },
  {
    "row_id": "ROW_455",
    "regimen": "Evolving treatment strategies",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_455"
  },
  {
    "row_id": "ROW_500",
    "regimen": "Targeting KRAS",
    "drugs": [],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_500"
  },
  {
    "row_id": "1914P",
    "regimen": "Sex differences in tolerability to Targeted Therapies",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1914P"
  },
  {
    "row_id": "ROW_519",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_519"
  },
  {
    "row_id": "2535eP",
    "regimen": "PSMA-PET CT scans for prostate cancer staging and surveillance",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_572",
    "regimen": "anti-EGFR rechallenge",
    "drugs": [
      "anti-EGFR"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "3201eP",
    "regimen": "earlier detection of lung cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_589",
    "regimen": "BRAF mt mCRC",
    "drugs": [],
    "biomarkers": [
      "BRAF"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_613",
    "regimen": "small things matter",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_901",
    "regimen": "State-of-the-art in 2025",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA32",
    "regimen": "Panitumumab retreatment followed by regorafenib",
    "drugs": [
      "Panitumumab",
      "regorafenib"
    ],
    "biomarkers": [
      "RAS",
      "BRAF"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2080eTiP",
    "regimen": "iza-bren (BL-B01D1) combinations",
    "drugs": [
      "iza-bren",
      "BL-B01D1"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1111",
    "regimen": "long-term patient-centred care",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1112",
    "regimen": "long-term patient-centred care",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1113",
    "regimen": "Summary and close",
    "trial_id": "ROW_1113",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_1155",
    "regimen": "New targets",
    "trial_id": "ROW_1155",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_1809",
    "regimen": "Optimising patient supportive care",
    "trial_id": "ROW_1809",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_1829",
    "regimen": "Advances in first-line strategies",
    "trial_id": "ROW_1829",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_1994",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_1994",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2005",
    "regimen": "Lung cancer care: Implementing shared decision-making",
    "trial_id": "ROW_2005",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2006",
    "regimen": "Discussion",
    "trial_id": "ROW_2006",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2031",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_2031",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2067",
    "regimen": "How to define an unfit population",
    "trial_id": "ROW_2067",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_2099",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_2099",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "891eP",
    "regimen": "anti-BRAF and anti-EGFR therapy",
    "drugs": [
      "anti-BRAF",
      "anti-EGFR"
    ],
    "biomarkers": [
      "BRAF V600E"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "LBA35",
    "regimen": "Iza-Bren (BL-B01D1) versus Physician's Choice of Chemotherapy",
    "drugs": [
      "Iza-Bren (BL-B01D1)",
      "Chemotherapy"
    ],
    "biomarkers": [
      "EGFR",
      "HER3"
    ],
    "modality": [
      "ADC",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "727MO",
    "regimen": "FOLFOX plus PANITUMUMAB according to a 'stop-and-go' strategy",
    "drugs": [
      "FOLFOX",
      "PANITUMUMAB"
    ],
    "biomarkers": [
      "RAS",
      "BRAF"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "931P",
    "regimen": "necitumumab",
    "drugs": [
      "necitumumab"
    ],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "WJOG15021M"
  },
  {
    "row_id": "855P",
    "regimen": "Larotrectinib",
    "drugs": [
      "Larotrectinib"
    ],
    "biomarkers": [
      "NTRK"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "933P",
    "regimen": "iza-bren (BL-B01D1)",
    "drugs": [
      "iza-bren (BL-B01D1)"
    ],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "phase": "Phase 1",
    "trial_id": "933P",
    "biomarkers": []
  },
  {
    "row_id": "1575P",
    "regimen": "Tocilizumab",
    "drugs": [
      "Tocilizumab"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "1575P",
    "biomarkers": []
  },
  {
    "row_id": "918O",
    "regimen": "telisotuzumab adizutecan (ABBV-400; Temab-A)",
    "drugs": [
      "telisotuzumab adizutecan (ABBV-400; Temab-A)"
    ],
    "population": "Other",
    "phase": "Phase 1",
    "trial_id": "918O",
    "biomarkers": []
  },
  {
    "row_id": "839P",
    "regimen": "Encorafenib, cetuximab, plus binimetinib",
    "drugs": [
      "Encorafenib",
      "cetuximab",
      "binimetinib"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "839P",
    "biomarkers": []
  },
  {
    "row_id": "738P",
    "regimen": "pertuzumab plus trastuzumab",
    "drugs": [
      "pertuzumab",
      "trastuzumab"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "738P",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "846P",
    "regimen": "Anti-EGFR Monoclonal Antibodies",
    "drugs": [
      "Anti-EGFR Monoclonal Antibodies"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "846P",
    "biomarkers": [
      "PIK3CA"
    ]
  },
  {
    "row_id": "2240P",
    "regimen": "Major KRAS Variants",
    "drugs": [],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2240P",
    "biomarkers": [
      "KRAS"
    ]
  },
  {
    "row_id": "800P",
    "regimen": "mCapOX plus cetuximab with mFOLFOX6 plus cetuximab",
    "drugs": [
      "mCapOX",
      "cetuximab",
      "mFOLFOX6"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "800P",
    "biomarkers": []
  },
  {
    "row_id": "2129P",
    "regimen": "Transarterial infusion chemotherapy and embolization (TAICE)",
    "drugs": [],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "2129P",
    "biomarkers": []
  },
  {
    "row_id": "2996P",
    "regimen": "Radioactive Iodine-Refractory Differentiated Thyroid Cancer treatment",
    "drugs": [
      "BRAF Mutation"
    ],
    "biomarkers": [
      "BRAF"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2996P"
  },
  {
    "row_id": "265eP",
    "regimen": "Flow SuperRCA for KRAS Mutation Detection",
    "drugs": [
      "KRAS Mutation"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "265eP"
  },
  {
    "row_id": "36eP",
    "regimen": "NCOA4 as an immunological and prognostic biomarker",
    "drugs": [],
    "biomarkers": [
      "NCOA4"
    ],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "36eP"
  },
  {
    "row_id": "3046eP",
    "regimen": "Co-Mutational Racial Disparities in EGFR positive Lung Cancer",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "3046eP"
  },
  {
    "row_id": "ROW_3217",
    "regimen": "Germline mutations testing",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_3217"
  },
  {
    "row_id": "1786O",
    "regimen": "AI for early-stage lung cancer recurrence prognosis",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1786O"
  },
  {
    "row_id": "1682P",
    "regimen": "BRAF plus MEK inhibitors treatment",
    "drugs": [
      "BRAF",
      "MEK inhibitors"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1682P"
  },
  {
    "row_id": "1753eP",
    "regimen": "Microdose Trial of [68Ga]Ga-R54",
    "drugs": [
      "[68Ga]Ga-R54"
    ],
    "biomarkers": [],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1753eP"
  },
  {
    "row_id": "171P",
    "regimen": "NTRK+ solid tumors treatment",
    "drugs": [],
    "biomarkers": [
      "NTRK"
    ],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "171P"
  },
  {
    "row_id": "3029eP",
    "regimen": "KRAS G12C inhibitors treatment",
    "drugs": [
      "KRAS G12C inhibitors"
    ],
    "biomarkers": [
      "ASS1",
      "EGFR",
      "KRAS"
    ],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "3029eP"
  },
  {
    "row_id": "249eP",
    "regimen": "systematic review and meta-analysis",
    "drugs": [],
    "biomarkers": [
      "EGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "687P",
    "regimen": "Targeted therapy",
    "drugs": [],
    "biomarkers": [
      "BRAF",
      "NTRK"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1646P",
    "regimen": "second-line BRAF/MEK inhibitors",
    "drugs": [
      "BRAF",
      "MEK"
    ],
    "biomarkers": [
      "BRAFV600"
    ],
    "modality": [],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "16P",
    "regimen": "TET2-Mutant Clonal Hematopoiesis",
    "drugs": [],
    "biomarkers": [
      "TET2"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1721P",
    "regimen": "External validation of Rachel score",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2991P",
    "regimen": "anlotinib plus sintilimab",
    "drugs": [
      "anlotinib",
      "sintilimab"
    ],
    "biomarkers": [
      "BRAF"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "68eP",
    "regimen": "promotes lung metastasis",
    "drugs": [],
    "biomarkers": [
      "GPX3"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "18P",
    "regimen": "Clinical Efficacy and Immune Mechanism of PD-1/CTLA-4 Bispecific Antibody Cadonilimab",
    "drugs": [
      "Cadonilimab"
    ],
    "biomarkers": [],
    "modality": [
      "Bispecific"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1643P",
    "regimen": "regorafenib combined with BRAF-/MEK-inhibitors",
    "drugs": [
      "regorafenib",
      "BRAF-inhibitors",
      "MEK-inhibitors"
    ],
    "biomarkers": [
      "BRAFV600"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "RegoMel"
  },
  {
    "row_id": "2214MO",
    "regimen": "telisotuzumab adizutecan",
    "drugs": [
      "telisotuzumab adizutecan",
      "ABBV-400",
      "Temab-A"
    ],
    "biomarkers": [
      "c-Met"
    ],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "2214MO"
  },
  {
    "row_id": "1645P",
    "regimen": "Combination of Encorafenib, Binimetinib and Palbociclib",
    "drugs": [
      "Encorafenib",
      "Binimetinib",
      "Palbociclib"
    ],
    "biomarkers": [
      "BRAF-Mutant"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1b",
    "trial_id": "1645P"
  },
  {
    "row_id": "1694eP",
    "regimen": "induction targeted therapy with immune checkpoint inhibitor therapy switch",
    "drugs": [
      "BRAF",
      "ICI"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1694eP",
    "biomarkers": []
  },
  {
    "row_id": "196eP",
    "regimen": "SOS1 inhibitor and EGFR inhibitor combinations",
    "drugs": [
      "BMS-986509",
      "adagrasib"
    ],
    "biomarkers": [
      "KRAS G12C",
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "196eP"
  },
  {
    "row_id": "1623P",
    "regimen": "switching from BRAF/MEK inhibition to immune checkpoint inhibition",
    "drugs": [
      "BRAF",
      "MEK",
      "ICI"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1623P",
    "biomarkers": []
  },
  {
    "row_id": "1647P",
    "regimen": "Dabrafenib/trametinib versus encorafenib/binimetinib",
    "drugs": [
      "Dabrafenib",
      "Trametinib",
      "Encorafenib",
      "Binimetinib"
    ],
    "biomarkers": [
      "BRAF"
    ],
    "modality": [
      "TKI"
    ],
    "population": "mUC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1647P"
  },
  {
    "row_id": "683P",
    "regimen": "Dual Immune Checkpoint Inhibition",
    "drugs": [
      "BRAF",
      "NRAS",
      "PD-L1",
      "C-KIT"
    ],
    "biomarkers": [
      "BRAF",
      "NRAS",
      "PD-L1",
      "C-KIT"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "683P"
  },
  {
    "row_id": "ROW_4650",
    "trial_id": "ROW_4650",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_4655",
    "trial_id": "ROW_4655",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_4671",
    "modality": [
      "IO"
    ],
    "trial_id": "ROW_4671",
    "drugs": [],
    "biomarkers": []
  }
]